At JPM Week 2025 in San Francisco, pharmaphorum editor-in-chief Jonah Comstock met with Rick Stewart, CEO of Achieve Life ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

Warren asked him to pledge not to receive any compensation from lawsuits against pharma companies as HHS secretary and four ...

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape relations. Regulation and deregulation may alter processes. And any ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

In today’s fast-paced world, threats can evolve quickly and without warning. As the pharmaceutical industry has operations and supply chains spanning the globe, companies are vulnerable to ...

AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation powers has stumbled at the first hurdle in a federal court. US judge Colm Connolly of US district court in Delaware ...